{
  "ticker": "IDT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970048",
  "id": "02970048",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250717",
  "time": "0849",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lw646x4y2qj0.pdf",
  "summary": "- **Partnership Announcement**: IDT signs MoU with NASDAQ-listed Gelteq to establish a dedicated manufacturing facility for gel-based pharmaceutical/nutraceutical products.  \n- **Key Terms**:  \n  - Gelteq to fund and build a purpose-built facility within IDT\u2019s GMP site.  \n  - Focus on regulatory compliance (FDA, TGA, APVMA) and rapid scale-up capability.  \n- **Strategic Impact**: Expands IDT\u2019s advanced delivery technologies and potential revenue streams.  \n\nNo capital-raising or trading-related material information identified.",
  "usage": {
    "prompt_tokens": 1438,
    "completion_tokens": 121,
    "total_tokens": 1559,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T22:58:24.007044"
}